Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,022 public trials 2,030 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

NCT03063632

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +33 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

NCT04135963

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Centro Clinico Academico Hospital de Braga Braga, Portugal
  • Centro Hospitalar e Universitario de Coimbra. EPE Coimbra, Portugal
  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPO) Lisbon, Portugal
  • Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria Lisbon, Portugal
View Trial Details
Completed

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

NCT02869633

Conditions
Blastoid Variant Mantle Cell Lymphoma, Chronic Disease, Disease Attributes, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
View Trial Details
Completed

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

NCT02417285

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Local Institution - 105 Borddeaux Cedex, France
  • Local Institution - 102 Marseille, France
  • Local Institution - 103 Pierre-Bénite, France
  • Local Institution - 101 Villejuif, France
View Trial Details
Completed

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

NCT02399085

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • UCLA - David Geffen School of Medicine Los Angeles, California, United States
  • Cancer Care - Torrance Memorial Physician Network Redondo Beach, California, United States
  • Central Coast Medical Oncology Corporation Santa Maria, California, United States
View all 57 locations
View Trial Details
Completed

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

NCT04198415

Conditions
Cancer, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +17 more
Locations
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 239524 Nagoya, Aichi-ken, Japan
  • Nagoya University Hospital /ID# 225300 Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital /ID# 240820 Nagoya, Aichi-ken, Japan
  • Toyohashi Municipal Hospital /ID# 227433 Toyohashi, Aichi-ken, Japan
View all 102 locations
View Trial Details

Related conditions